On April 5, 2018 Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF), a biotech company developing REOLYSIN (pelareorep), an intravenously delivered immuno-oncolytic virus creating an inflamed phenotype, reported that it will be presenting at the MicroCap Conference, being held at the Essex House in New York City on April 9 – 10, 2018 (Press release, Oncolytics Biotech, APRIL 5 2018, View Source [SID1234525207]). The Company’s presentation will be on April 10th at 8:30 am ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Matt Coffey, President & Chief Executive Officer, will present a corporate overview, focusing on pelareorep’s mechanism of action and the Company’s lead program in HR+/HER2- metastatic breast cancer. The presentation will also describe Oncolytics’ pipeline expansion programs, focusing on combination therapies of REOLYSIN with other immuno-oncology drugs, including Merck’s Keytruda and targeted immunomodulatory drugs, including Celgene’s Revlimid and Imnovid.
The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity for investors to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other microcap investors.
A live audio link to the webcast session will be available on the Company’s website at View Source It is recommended that listeners log on 10 minutes in advance of a live session to register and download any necessary software. An audio replay will be accessible approximately two hours following the presentation on the Oncolytics website.